Safety issues relating to long‐term treatment with histamine H2‐receptor antagonists

@article{Sabesin1993SafetyIR,
  title={Safety issues relating to long‐term treatment with histamine H2‐receptor antagonists},
  author={Seymour M. Sabesin},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={1993},
  volume={7}
}
  • S. Sabesin
  • Published 1 December 1993
  • Medicine, Biology
  • Alimentary Pharmacology & Therapeutics
H2‐receptor antagonist therapy is associated with a low incidence of adverse reactions. Adverse events reported in clinical trials of ranitidine in daily doses of up to 1200 mg include headache, tiredness and mild gastrointestinal disturbances, but the incidence is similar to or less than that for placebo. High doses of cimetidine (> 5 g/day) can cause reversible impotence or gynaecomastia. While ranitidine exhibits no clinically significant drug‐drug interactions, cimetidine interacts with… 

High‐dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs.

High dose ranitidine is effective for the prevention of recurrent duodenal ulcer but not for recurrent gastric ulcer in rheumatoid arthritis patients taking NSAIDs.

Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.

3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period are reported.

Pharmacogenomics for the efficacy and side effects of antihistamines

Current reports in pharmacogenomics are summarized, aiming to contribute to future research in antihistamines and clinical guidance for antihistamine use in individualized medicine.

Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease

Esophageal pH-impedance monitoring helps to distinguish functional heartburn from true GERD, and psychologic medication and cognitive behavior therapy are further therapy options instead of PPIs.

Side effects of drug treatments for gastro-oesophageal reflux disease: current controversies

A critical review of the published literature and the clinical significance of reported side effects of proton pump inhibitors and histamine-2 receptor antagonists in gastro-oesophageal reflux disease.

Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent

It is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential ofcimetidine as an anti-cancer therapeutic is warranted.

Association Between Acid-Suppressive Agents’ Use and Risk of Hepatocellular Carcinoma

The use of AsAs increased the risk of HCC in patients with UGIDs, and the effect of ASAs was dose dependent, and in addition, UGID alone increased therisk of H CC.

Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy

The present review summarizes the pharmacokinetic and pharmacodynamic of different components of anaesthetic antacids and its clinical use across different gastrointestinal indications, for generalists and specialists, based on existing evidences.

References

SHOWING 1-10 OF 26 REFERENCES

Haematological Adverse Effects of Histamine H2-Receptor Antagonists

Histamine H2-receptor antagonists are widely used in the treatment of gastrointestinal diseases related to gastric acid hypersecretion and may theoretically contribute to the occurrence of iron or cobalamin deficiency anaemia.

Safety profile of long‐term H2‐antagonist therapy

  • J. Lewis
  • Medicine
    Alimentary pharmacology & therapeutics
  • 1991
The safety profile of low‐dose maintenance therapy with H2‐antagonists for duodenal ulcer disease suggests that these agents can be given safely for several years and probably much longer. Because

The drug interaction potential of ranitidine: an update.

Final report on the United States Multicenter Trial comparing ranitidine to cimetidine as maintenance therapy following healing of duodenal ulcer.

  • S. Silvis
  • Medicine
    Journal of clinical gastroenterology
  • 1985
At the doses prescribed, ranitidine was superior to cimetidine as maintenance therapy in duodenal ulcer disease and no significant drug-related adverse effects were seen with either drug during this 1 year trial.

Ranitidine at very large doses does not inhibit theophylline elimination

While case reports indicate ranitidine may inhibit theophylline metabolism specifically and drug metabolism in general, a controlled study was not able in this controlled study to detect any effect of ran itidine on theophyLLine elimination even at runningitidine doses up to fourteenfold greater than are generally prescribed.

10. Medical Events Occurring in Patients with Duodenal Ulcer Disease during Maintenance Treatment with Ranitidine

Nausea, diarrhoea, and constipation were the most frequent complaints related to the gastrointestinal tract, but in most patients these symptoms were not related to treatment with ranitidine.

A study of the interaction of omeprazole and warfarin in anticoagulated patients.

Patients on continuous therapy with warfarin were given omeprazole 20 mg once daily and placebo each for 3 weeks according to a two-centre randomised double-blind cross-over design and the anticoagulant effect was assessed using the Trombotest.